Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Cipher Pharmac Cmn (CPHR)

Cipher Pharmac Cmn (CPHR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Cipher Pharmac Cmn 2345 Argentia Road Suite 100A Mississauga ON L5N 8K4

www.cipherpharma.com P: 905-602-5840

Description:

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company. It develops improved formulations of existing drugs. The Company's core capabilities include clinical and regulatory affairs, product licensing, supply chain management, and marketing and sales. It has three commercial products and a fourth in development. The Company's products include a fenofibrate formulation marketed in the United States as Lipofen (R); an extended-release tramadol, which is marketed in the United States as ConZip (R) and in Canada as Durela (R); and a novel formulation of the acne treatment isotretinoin, which is marketed in the United States as Absorica (TM) and in Canada as Epuris (R). Cipher Pharmaceuticals Inc. is based in Mississauga, Canada.

Key Statistics

Overview:

Market Capitalization, $K 78,350
Shares Outstanding, K 26,190
Annual Sales, $ 34,410 K
Annual Net Income, $ 1,770 K
Last Quarter Sales, $ 9,270 K
Last Quarter Net Income, $ -21,790 K
60-Month Beta 1.39
% of Institutional Shareholders 25.09%

Growth:

1-Year Return -24.69%
3-Year Return -63.27%
5-Year Return 0.00%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Latest Earnings Date 11/11/16
Earnings Per Share ttm -0.17
EPS Growth vs. Prev Qtr -33.33%
EPS Growth vs. Prev Year -100.00%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

CPHR Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -9.83%
Return-on-Assets % -4.40%
Profit Margin % 5.14%
Debt/Equity 55.04
Price/Sales 2.28
Price/Cash Flow 9.42
Price/Book 2.66
Book Value/Share 1.12
Interest Coverage 0.07
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar